🏛️ Verified NIH Record • Updated 2026-05-20

A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (NCT02671435)

🔵 Active, Not Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: MedImmune LLC

🩺 Plain-English Summary (8th-Grade Level)

This is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (PK), pharmacodynamics, and immunogenicity of durvalumab (MEDI4736) in combination with monalizumab (IPH2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (IPH2201) standard of care systemic therapy with or without biological agent and monalizumab (IPH2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (CRC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (5 items).

Location: Research Site — Birmingham, Alabama

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria
  • Prior treatment with immunotherapy agents. Prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor.
  • Prior participation in clinical studies that include durvalumab alone or in combination, where the study has registrational intent and the analyses for the primary endpoint have not yet been completed
  • Receipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of study treatment
  • Any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. Concurrent use of hormones for non-cancer-related conditions is acceptable.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (49 Sites)

  • Research Site — Birmingham, Alabama
  • Research Site — Scottsdale, Arizona
  • Research Site — Duarte, California
  • Research Site — La Jolla, California
  • Research Site — Los Angeles, California
  • Research Site — Sacramento, California
  • Research Site — Santa Monica, California
  • Research Site — Aurora, Colorado
  • Research Site — Tampa, Florida
  • Research Site — Chicago, Illinois
  • Research Site — Baltimore, Maryland
  • Research Site — Boston, Massachusetts
  • Research Site — Detroit, Michigan
  • Research Site — New Brunswick, New Jersey
  • Research Site — New Hyde Park, New York
  • Research Site — New York, New York
  • Research Site — The Bronx, New York
  • Research Site — Providence, Rhode Island
  • Research Site — Nashville, Tennessee
  • Research Site — Dallas, Texas
  • Research Site — San Antonio, Texas
  • Research Site — Salt Lake City, Utah
  • Research Site — Blacktown,
  • Research Site — Clayton,
  • Research Site — Waratah,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗